Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224951890> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W4224951890 endingPage "629" @default.
- W4224951890 startingPage "618" @default.
- W4224951890 abstract "Sintilimab is a selective PD-1 inhibitor with efficacy in advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) patients. This study evaluated the cost-effectiveness of sintilimab + chemotherapy versus camrelizumab + chemotherapy as the first-line treatment for locally advanced or metastatic nonsquamous NSCLC in Chinese patients. In addition, this study aimed to reveal the impact of the reference treatment choice on the incremental cost-effectiveness ratio (ICER) results.A partitioned survival model (PSM) with three health states was constructed in a 3-week cycle with a lifetime horizon from the Chinese healthcare system perspective. Anchored matching adjusted indirect comparison was used for survival analyses based on individual patient data from Orient-11. Sintilimab + chemotherapy was chosen as the reference treatments in scenarios 1 and 2, while the camrelizumab + chemotherapy was chosen as the reference treatments in scenario 3. The utility values of different health states were derived from the patient-level European Organization for Research and Treatment Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) scores by mapping to the EQ-5D-5L, and QALYs were calculated as the health outcomes. One-way deterministic sensitivity analysis (DSA) and probability sensitivity analysis (PSA) were performed to explore model uncertainty.Compared to camrelizumab + chemotherapy, sintilimab + chemotherapy was associated with higher effectiveness (incremental QALYs ranged from 0.13-0.62) and lower total costs (incremental costs ranged from $1,099-$5,201), resulting in an ICER ranging from $6,440-$8,454/QALY.Sintilimab + chemotherapy is a cost-effective option compared with camrelizumab + chemotherapy as the first-line treatment for locally advanced or metastatic nonsquamous NSCLC in China." @default.
- W4224951890 created "2022-04-28" @default.
- W4224951890 creator A5000152207 @default.
- W4224951890 creator A5010267827 @default.
- W4224951890 creator A5019527805 @default.
- W4224951890 creator A5040533308 @default.
- W4224951890 creator A5045963906 @default.
- W4224951890 creator A5076952654 @default.
- W4224951890 creator A5064736419 @default.
- W4224951890 date "2022-05-15" @default.
- W4224951890 modified "2023-10-09" @default.
- W4224951890 title "Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China" @default.
- W4224951890 cites W1982967337 @default.
- W4224951890 cites W2017628547 @default.
- W4224951890 cites W2022946202 @default.
- W4224951890 cites W2296800272 @default.
- W4224951890 cites W2338340952 @default.
- W4224951890 cites W2900645032 @default.
- W4224951890 cites W2900981012 @default.
- W4224951890 cites W2944210907 @default.
- W4224951890 cites W2950219174 @default.
- W4224951890 cites W2959432976 @default.
- W4224951890 cites W3026296708 @default.
- W4224951890 cites W3047859155 @default.
- W4224951890 cites W3089391803 @default.
- W4224951890 cites W3111665711 @default.
- W4224951890 cites W3128646645 @default.
- W4224951890 cites W3133497257 @default.
- W4224951890 cites W3143019137 @default.
- W4224951890 cites W3178295071 @default.
- W4224951890 cites W3187725522 @default.
- W4224951890 doi "https://doi.org/10.1080/13696998.2022.2071066" @default.
- W4224951890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35475459" @default.
- W4224951890 hasPublicationYear "2022" @default.
- W4224951890 type Work @default.
- W4224951890 citedByCount "16" @default.
- W4224951890 countsByYear W42249518902022 @default.
- W4224951890 countsByYear W42249518902023 @default.
- W4224951890 crossrefType "journal-article" @default.
- W4224951890 hasAuthorship W4224951890A5000152207 @default.
- W4224951890 hasAuthorship W4224951890A5010267827 @default.
- W4224951890 hasAuthorship W4224951890A5019527805 @default.
- W4224951890 hasAuthorship W4224951890A5040533308 @default.
- W4224951890 hasAuthorship W4224951890A5045963906 @default.
- W4224951890 hasAuthorship W4224951890A5064736419 @default.
- W4224951890 hasAuthorship W4224951890A5076952654 @default.
- W4224951890 hasBestOaLocation W42249518901 @default.
- W4224951890 hasConcept C112930515 @default.
- W4224951890 hasConcept C126322002 @default.
- W4224951890 hasConcept C143998085 @default.
- W4224951890 hasConcept C159110408 @default.
- W4224951890 hasConcept C2776256026 @default.
- W4224951890 hasConcept C2776694085 @default.
- W4224951890 hasConcept C2779900020 @default.
- W4224951890 hasConcept C2779951463 @default.
- W4224951890 hasConcept C3019080777 @default.
- W4224951890 hasConcept C515549039 @default.
- W4224951890 hasConcept C64332521 @default.
- W4224951890 hasConcept C71924100 @default.
- W4224951890 hasConceptScore W4224951890C112930515 @default.
- W4224951890 hasConceptScore W4224951890C126322002 @default.
- W4224951890 hasConceptScore W4224951890C143998085 @default.
- W4224951890 hasConceptScore W4224951890C159110408 @default.
- W4224951890 hasConceptScore W4224951890C2776256026 @default.
- W4224951890 hasConceptScore W4224951890C2776694085 @default.
- W4224951890 hasConceptScore W4224951890C2779900020 @default.
- W4224951890 hasConceptScore W4224951890C2779951463 @default.
- W4224951890 hasConceptScore W4224951890C3019080777 @default.
- W4224951890 hasConceptScore W4224951890C515549039 @default.
- W4224951890 hasConceptScore W4224951890C64332521 @default.
- W4224951890 hasConceptScore W4224951890C71924100 @default.
- W4224951890 hasFunder F4320317608 @default.
- W4224951890 hasIssue "1" @default.
- W4224951890 hasLocation W42249518901 @default.
- W4224951890 hasLocation W42249518902 @default.
- W4224951890 hasOpenAccess W4224951890 @default.
- W4224951890 hasPrimaryLocation W42249518901 @default.
- W4224951890 hasRelatedWork W2065879558 @default.
- W4224951890 hasRelatedWork W2413020017 @default.
- W4224951890 hasRelatedWork W2472742574 @default.
- W4224951890 hasRelatedWork W2598700445 @default.
- W4224951890 hasRelatedWork W2754292714 @default.
- W4224951890 hasRelatedWork W2952061954 @default.
- W4224951890 hasRelatedWork W3058998032 @default.
- W4224951890 hasRelatedWork W3125858761 @default.
- W4224951890 hasRelatedWork W4300981573 @default.
- W4224951890 hasRelatedWork W4380987560 @default.
- W4224951890 hasVolume "25" @default.
- W4224951890 isParatext "false" @default.
- W4224951890 isRetracted "false" @default.
- W4224951890 workType "article" @default.